[A case study of leukemia with irregular anti-Ce IgG antibody]

Area of Science:

• Transfusion Medicine
• Immunology
• Hematology

Background:

• Compatibility testing is crucial for safe blood transfusions, especially in patients with complex antibody profiles.
• Leukemia patients often require multiple transfusions, increasing the risk of alloimmunization.
• Irregular antibodies can complicate transfusion management and lead to hemolytic transfusion reactions.

Observation:

• During routine compatibility testing for a leukemia patient, an irregular antibody was detected.
• Antibody identification using panel cells revealed the specificity to be anti-Ce.
• The antibody was confirmed as a clinically significant IgG class antibody with dual specificity (anti-C and anti-e).

Findings:

• The identified anti-Ce antibody presents a significant challenge for finding compatible blood units.
• The prevalence of Ce antigen-negative donors is very low, estimated at only 2%-3%.
• This low donor availability poses a substantial risk for transfusion support in this patient.

Implications:

• Urgent need for strategies to manage patients with rare antibodies like anti-Ce.
• Importance of extended antigen matching beyond ABO and RhD for transfusion-dependent patients.
• Potential development of specialized donor registries or in-vitro methods for antigen-negative blood sourcing.